An Open-Label Study of the Safety and Tolerability of Combining 20089 (Triamcinolone Acetonide Intravitreal Injection) When Used Adjunctively With Lucentis® 0.5 mg Intravitreal Injection in Subjects With Subfoveal Neovascular AMD

Trial Profile

An Open-Label Study of the Safety and Tolerability of Combining 20089 (Triamcinolone Acetonide Intravitreal Injection) When Used Adjunctively With Lucentis® 0.5 mg Intravitreal Injection in Subjects With Subfoveal Neovascular AMD

Completed
Phase of Trial: Phase I/II

Latest Information Update: 22 Oct 2014

At a glance

  • Drugs IBI 20089 (Primary) ; Ranibizumab
  • Indications Age-related macular degeneration; Choroidal neovascularisation
  • Focus Adverse reactions
  • Most Recent Events

    • 19 Oct 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
    • 14 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top